First Time Loading...

Taro Pharmaceutical Industries Ltd
NYSE:TARO

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Watchlist
Price: 42.3 USD -0.26%
Updated: May 13, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

2.2B
+2%
Assets
Growth Rates:
1 Year
+2%
3 Years
-9%
5 Years
+5%
7 Years
-4%
10 Years
+80%
384.1m
+3%
Liabilities
Growth Rates:
1 Year
-3%
3 Years
-37%
5 Years
+67%
7 Years
+53%
10 Years
+48%
1.8B
+2%
Equity
Growth Rates:
1 Year
+3%
3 Years
+1%
5 Years
-3%
7 Years
-11%
10 Years
+88%

Balance Sheet Decomposition
Taro Pharmaceutical Industries Ltd

2.2B
Assets
384.1m
Liabilities
2.2B
Assets
384.1m
Liabilities
Current Assets 1.3B
Cash & Short-Term Investments 902.2m
Receivables 230.4m
Other Current Assets 214.8m
Non-Current Assets 815.8m
Long-Term Investments 403.5m
PP&E 218.4m
Intangibles 17.2m
Other Non-Current Assets 176.6m
Current Liabilities 374.1m
Accounts Payable 51.2m
Other Current Liabilities 322.9m
Non-Current Liabilities 10m
Other Non-Current Liabilities 10m

Balance Sheet
Taro Pharmaceutical Industries Ltd

Rotate your device to view
Balance Sheet
Currency: USD
Mar-2014 Mar-2015 Mar-2016 Mar-2017 Mar-2018 Mar-2019 Mar-2020 Mar-2021 Mar-2022 Mar-2023
Assets
Cash & Cash Equivalents
210
482
577
600
577
568
513
605
299
275
Cash
0
0
0
0
0
0
0
0
48
120
Cash Equivalents
210
482
577
600
577
568
513
605
251
155
Short-Term Investments
422
438
652
786
846
482
595
419
522
576
Total Receivables
162
265
287
329
323
278
264
254
294
248
Accounts Receivables
139
222
239
204
207
238
235
214
247
202
Other Receivables
23
43
49
125
117
40
29
41
47
45
Inventory
118
120
139
141
145
148
153
180
210
227
Other Current Assets
140
208
223
142
6
7
7
13
13
12
Total Current Assets
1 051
1 514
1 878
1 999
1 897
1 483
1 533
1 471
1 338
1 336
PP&E Net
151
153
160
180
194
206
212
208
205
194
PP&E Gross
151
153
160
180
194
206
212
208
205
194
Accumulated Depreciation
213
217
217
218
234
237
255
277
311
332
Intangible Assets
17
13
8
6
7
9
8
7
47
64
Goodwill
7
7
7
7
7
7
7
7
12
17
Note Receivable
53
46
0
0
0
0
0
0
0
0
Long-Term Investments
0
0
115
71
226
304
460
557
435
405
Other Long-Term Assets
5
4
20
27
103
126
121
157
139
119
Other Assets
7
7
7
7
7
7
7
7
12
17
Total Assets
1 284
N/A
1 738
+35%
2 188
+26%
2 290
+5%
2 433
+6%
2 135
-12%
2 341
+10%
2 407
+3%
2 176
-10%
2 136
-2%
Liabilities
Accounts Payable
53
63
67
53
62
67
66
78
88
91
Accrued Liabilities
30
35
36
33
37
37
37
42
51
49
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
12
1
0
0
0
0
0
0
0
0
Other Current Liabilities
159
211
142
123
116
112
119
556
293
246
Total Current Liabilities
253
310
246
210
216
217
223
676
432
386
Long-Term Debt
6
5
0
0
0
0
0
0
0
0
Deferred Income Tax
2
2
2
2
3
3
3
2
0
0
Minority Interest
5
6
6
6
5
6
6
8
0
0
Other Liabilities
3
4
3
4
4
4
5
33
33
19
Total Liabilities
269
N/A
326
+21%
257
-21%
222
-13%
228
+3%
230
+1%
237
+3%
703
+196%
465
-34%
405
-13%
Equity
Common Stock
1
1
1
1
1
1
1
1
1
1
Retained Earnings
970
1 454
1 995
2 451
2 662
2 481
2 725
2 339
2 389
2 414
Additional Paid In Capital
262
262
262
262
262
262
262
262
262
262
Treasury Stock
194
194
204
499
610
695
722
747
771
771
Other Equity
23
111
123
148
110
144
163
152
169
175
Total Equity
1 016
N/A
1 412
+39%
1 931
+37%
2 068
+7%
2 205
+7%
1 906
-14%
2 104
+10%
1 704
-19%
1 711
+0%
1 731
+1%
Total Liabilities & Equity
1 284
N/A
1 738
+35%
2 188
+26%
2 290
+5%
2 433
+6%
2 135
-12%
2 341
+10%
2 407
+3%
2 176
-10%
2 136
-2%
Shares Outstanding
Common Shares Outstanding
43
43
43
41
39
39
38
38
38
38

See Also

Summary
TARO intrinsic value, competitors valuation, and company profile.
DCF Valuation
TARO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TARO stock valuation using valuation multiples.
Wall Street Estimates
TARO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TARO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.